S100A6, Calumenin and Cytohesin 2 as Biomarkers for Cutaneous Involvement in Systemic Sclerosis Patients: A Case...

Area of Science:

• Immunology
• Proteomics
• Autoimmune Diseases

Background:

• Systemic sclerosis (Ssc) is an autoimmune disease with poorly understood pathophysiology.
• Numerous candidate proteomic biomarkers require validation in independent Ssc cohorts.
• This study aimed to validate S100A6, calumenin, and cytohesin 2 as circulating biomarkers for Ssc.

Purpose of the Study:

• To confirm S100A6, calumenin, and cytohesin 2 as valid biomarkers in an independent cohort of Ssc patients.
• To investigate the association between these biomarkers and clinical characteristics of Ssc.
• To assess the predictive capacity of these biomarkers for Ssc manifestations.

Main Methods:

• Serum levels of S100A6, calumenin, and cytohesin 2 were measured using commercial ELISA kits.
• The study included 53 Ssc patients and 26 age- and gender-matched healthy controls.
• Statistical analyses were performed to correlate biomarker levels with clinical Ssc features.

Main Results:

• Serum concentrations of calumenin, S100A6, and cytohesin 2 were significantly elevated in Ssc patients compared to controls.
• Calumenin levels correlated with extensive cutaneous fibrosis, Raynaud phenomenon frequency, and low complement levels.
• S100A6 levels correlated with digital ulcers, while cytohesin 2 levels were associated with telangiectasia and pulmonary artery pressure.

Conclusions:

• Serum calumenin, S100A6, and cytohesin 2 are confirmed biomarkers for Ssc in an independent patient group.
• Calumenin demonstrated the highest predictive value for cutaneous Ssc manifestations.
• Further research is warranted to explore the prognostic implications and therapeutic potential of these biomarkers.